These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 8480192)

  • 1. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey.
    Hay CR; Lozier JN; Lee CA; Laffan M; Tradati F; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A; Teitel J; Mannucci PM; Kasper CK
    Thromb Haemost; 1996 Jan; 75(1):25-9. PubMed ID: 8713775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies.
    Gatti L; Mannucci PM
    Thromb Haemost; 1984 Jul; 51(3):379-84. PubMed ID: 6437005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J; Rzymkiewicz L; Lopaciuk S
    Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of factor VIII inhibitors in non-hemophilic patients.
    Green D
    Prog Clin Biol Res; 1984; 150():337-52. PubMed ID: 6431438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical patterns of hemophilic patients who develop inhibitors.
    McMillan CW
    Prog Clin Biol Res; 1984; 150():31-44. PubMed ID: 6431436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of treatment with porcine factor VIII.
    Gringeri A; Santagostino E; Tradati F; Giangrande PL; Mannucci PM
    Thromb Haemost; 1991 Mar; 65(3):245-7. PubMed ID: 1904652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current clinical aspects in hemophilia treatment].
    Meili EO
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1332-41. PubMed ID: 2508219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of factor VIII inhibitors--a general overview.
    White GC; Roberts HR
    Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.